Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Acquires $3,400,000.00 in Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Redmile Group, Llc purchased 200,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $3,400,000.00. Following the transaction, the insider directly owned 982,854 shares in the company, valued at approximately $16,708,518. The trade was a 25.55% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Redmile Group, Llc also recently made the following trade(s):

• On Thursday, August 6th, Redmile Group, Llc acquired 400,000 shares of Attovia Therapeutics stock. The stock was purchased at an average cost of $17.00 per share, with a total value of $6,800,000.00.

Attovia Therapeutics Price Performance

Shares of NASDAQ:ATTO opened at $20.17 on Monday. Attovia Therapeutics, Inc. has a twelve month low of $18.64 and a twelve month high of $22.79.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. raised its stake in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after buying an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent reporting period.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.